FDA approves Regeneron asthma drug

Regeneron Pharmaceuticals was awarded federal approval Friday to market its Dupixent drug to treat patients with moderate to severe asthma. The drug developer, which makes bulk medications at its East Greenbush, New York, manufacturing complex, already had been marketing the medication for use in patients with eczema or atopic dermatitis. The U.S. Food and Drug Administration approved Dupixent for eczema patients in March 2017. Then, late last week, the FDA gave Regeneron (Nasdaq: REGN) and its…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news